Analysis of Inventory
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Analysis of Liquidity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Geographic Areas
- Enterprise Value to EBITDA (EV/EBITDA)
- Enterprise Value to FCFF (EV/FCFF)
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Selected Financial Data since 2005
- Return on Assets (ROA) since 2005
- Price to Operating Profit (P/OP) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Inventory Disclosure
Regeneron Pharmaceuticals Inc., balance sheet: inventory
US$ in thousands
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Raw materials | |||||||||||
| Work-in-process | |||||||||||
| Finished goods | |||||||||||
| Deferred costs | |||||||||||
| Inventories |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- Inventory Components Trends
- The raw materials inventory demonstrated a generally upward trend over the five-year period, increasing from approximately 459.4 million US dollars in 2020 to 879.5 million US dollars in 2024. This represents a near doubling of raw materials held, although a slight decline was observed in 2023 compared to 2022.
- Work-in-process inventory showed more variability but overall growth. It decreased from about 904.6 million in 2020 to 707.2 million in 2021, followed by steady increases in the subsequent years, reaching 1.3423 billion US dollars by 2024. This strong growth suggests expanding production activities or longer production cycles.
- Finished goods inventory fluctuated, starting at 121.7 million in 2020, dropping notably to 73.7 million in 2021, then increasing to 98.6 million in 2022 and peaking at 147.3 million in 2023 before a slight decrease to 139.8 million in 2024. The overall trend indicates variability in inventory management or sales demand fluctuations.
- Deferred costs experienced a steady increase from 430.9 million in 2020 to 725.7 million in 2024. The rise was particularly notable in the last year, with a substantial jump from approximately 522.1 million in 2023 to 725.7 million in 2024, potentially reflecting increased prepaid expenses or capitalized costs.
- Total inventories grew consistently from 1.9166 billion US dollars in 2020 to 3.0873 billion in 2024. The pace of increase accelerated notably after 2021, underscoring an expanding stock of resources and capital tied in inventory.
- Insights
- The overall growth in inventories and deferred costs suggests an expansion in operational scale or a strategic buildup of stock to support future production or sales. The increase in work-in-process inventory may indicate longer manufacturing lead times or increased complexity in production. Fluctuations in finished goods inventory could reflect changing demand patterns or adjustments in sales forecasting. The significant jump in deferred costs in the final year merits further investigation to determine its nature and impact on cash flows.